NEJM：奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌

2019-12-19 MedSci MedSci原创

奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌效果显著

奥拉帕尼对新近诊断为晚期卵巢癌并伴有BRCA突变患者的维持治疗具有重要的临床价值。近日研究人员考察了奥拉帕尼联合贝伐单抗对全部卵巢癌患者的疗效。

新诊断的、晚期、高级别卵巢癌患者参与研究，在一线铂-紫杉烷化疗加贝伐单抗治疗后有反应。无论手术结果或BRCA突变情况，患者随机接受奥拉帕尼(每日两次，300毫克)或安慰剂，持续24个月；所有患者每3周服用一次贝伐单抗，剂量为每公斤15毫克，共15个月。研究的主要终点为疾病进展或死亡。

806名患者中，537名患者接受了奥拉帕尼治疗，269名患者接受了安慰剂治疗。中位随访22.9个月后，奥拉帕尼+贝伐单抗的中位无进展生存期为22.1个月，安慰剂+贝伐单抗的中位无进展生存期为16.6个月（疾病进展或死亡的危险比为0.59）。同源重组缺陷阳性(HRD)的肿瘤患者中，奥拉帕尼组vs.安慰剂组疾病进展或死亡危险比为0.33，在BRCA突变的肿瘤，中位无进展生存期分别为37.2 vs.17.7个月，无BRCA突变的HRD阳性肿瘤患者的中位无进展生存期分别为，28.1vs.16.6个月，疾病进展或死亡危险比为0.43。

研究认为，奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌效果显著。

原始出处：

Isabelle Ray-Coquard et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med， December 19， 2019.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=897970, encodeId=b8f889e97047, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>，绝佳搭配！不过，<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果联合贝伐单抗或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>，估计效果也不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=291, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44546, encryptionId=41f54454653, topicName=奥拉帕利), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=47363, encryptionId=af7b4e36370, topicName=尼拉帕利), TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:06:49 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394567, encodeId=1931139456eca, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477046, encodeId=4c9c14e7046ed, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035056, encodeId=016510350563b, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 19 21:35:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
2020-11-09 lovetcm

#奥拉帕利#联合#贝伐单抗#，绝佳搭配！不过，#尼拉帕利#如果联合贝伐单抗或#安罗替尼#，估计效果也不错

291 0
[GetPortalCommentsPageByObjectIdResponse(id=897970, encodeId=b8f889e97047, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>，绝佳搭配！不过，<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果联合贝伐单抗或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>，估计效果也不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=291, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44546, encryptionId=41f54454653, topicName=奥拉帕利), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=47363, encryptionId=af7b4e36370, topicName=尼拉帕利), TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:06:49 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394567, encodeId=1931139456eca, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477046, encodeId=4c9c14e7046ed, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035056, encodeId=016510350563b, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 19 21:35:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
2019-12-21 siiner

#晚期卵巢癌#

78 0
[GetPortalCommentsPageByObjectIdResponse(id=897970, encodeId=b8f889e97047, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>，绝佳搭配！不过，<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果联合贝伐单抗或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>，估计效果也不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=291, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44546, encryptionId=41f54454653, topicName=奥拉帕利), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=47363, encryptionId=af7b4e36370, topicName=尼拉帕利), TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:06:49 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394567, encodeId=1931139456eca, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477046, encodeId=4c9c14e7046ed, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035056, encodeId=016510350563b, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 19 21:35:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
2019-12-21 sunrural_42825359

#贝伐#

78 0
[GetPortalCommentsPageByObjectIdResponse(id=897970, encodeId=b8f889e97047, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=aeef922031b' target=_blank style='color:#2F92EE;'>#贝伐单抗#</a>，绝佳搭配！不过，<a href='/topic/show?id=af7b4e36370' target=_blank style='color:#2F92EE;'>#尼拉帕利#</a>如果联合贝伐单抗或<a href='/topic/show?id=a20e45830e0' target=_blank style='color:#2F92EE;'>#安罗替尼#</a>，估计效果也不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=291, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44546, encryptionId=41f54454653, topicName=奥拉帕利), TopicDto(id=92203, encryptionId=aeef922031b, topicName=贝伐单抗), TopicDto(id=47363, encryptionId=af7b4e36370, topicName=尼拉帕利), TopicDto(id=45830, encryptionId=a20e45830e0, topicName=安罗替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 09 15:06:49 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394567, encodeId=1931139456eca, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477046, encodeId=4c9c14e7046ed, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sat Dec 21 09:35:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035056, encodeId=016510350563b, content=顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Dec 19 21:35:00 CST 2019, time=2019-12-19, status=1, ipAttribution=)]
2019-12-19 旺医

顶刊就是顶刊，谢谢梅斯带来这么高水平的研究报道，我们科里同事经常看梅斯，分享梅斯上的信息

107 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

NEJM：奥拉帕尼联合贝伐单抗一线治疗晚期卵巢癌

相关资讯

科室

工具

服务